12:00 AM
 | 
Jan 23, 2012
 |  BioCentury  |  Product Development

Biocon's MOA bet

Biocon hopes safety will differentiate its anti-CD6 mAb from TNFs in psoriasis

Though a Phase III trial of Biocon Ltd.'s anti-CD6 mAb itolizumab did not show as much efficacy as other biologics in psoriasis, the biotech thinks lower infection rates could differentiate the mAb from the anti-TNFs.

Biocon this month announced itolizumab met the primary endpoint of PASI 75 improvement compared to placebo after 12 weeks (36% vs. 2%, p<0.0043) in the Indian Phase III TREAT-PLAQ trial in 223 patients with moderate to severe psoriasis.

A 34% placebo-adjusted PASI 75 response rate doesn't stack up well against other biologics. For instance, Stelara ustekinumab showed placebo-adjusted PASI 75 response rates of 63-72% after 12 weeks...

Read the full 504 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >